Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Efavirenz to Raltegravir for CNS Toxicity
NCT01195467Phase 3Completed
- Sponsor
- St Stephen's AIDS Trust
- Start
- Oct 2010
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by St Stephen's AIDS Trust. Started Oct 2010; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01195467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01195467.